Syncom Formulations (India) News

Syncom Formulations Board Meet Set for Feb 12, 2026

Syncom Formulations (India) Limited has scheduled its board meeting for February 12, 2026, to consider and approve Q3FY26 unaudited financial results for quarter and nine months ended December 31, 2025.

Syncom Formulations Faces ₹1.42 Cr GST Demand

Syncom Formulations receives revised GST demand notice of ₹1.42 crores including penalty for ineligible input tax credits, plans to appeal the decision.

Syncom Formulations Reports Mixed Q2 Performance with Revenue Decline and Profit Drop

Syncom Formulations (India) Limited reported quarterly results for the period ended September 30, 2025. The company's revenue from operations decreased to Rs 12,143.51 lakhs compared to Rs 16,546.69 lakhs in the previous quarter. Net profit for the quarter stood at Rs 1,572.93 lakhs, down from Rs 1,695.00 lakhs in the prior quarter. For the half-year period, revenue reached Rs 28,690.20 lakhs versus Rs 18,735.68 lakhs in the corresponding previous period. The company operates in three business segments: Pharmaceuticals, Drugs & Formulations, Trading of Commodities, and Renting of Property. Basic earnings per share for the quarter was Rs 0.18 compared to Rs 0.21 in the previous quarter. The results were approved by the Board of Directors at their meeting held on November 12, 2025.